RARITAN, N.J., July 7, 2021 /CNW/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play, in-vitro diagnostics (IVD) companies, today announced its distribution agreement ...

-- Ortho's new VITROS(R) Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

• Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in ...

- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...

After a blockbuster two years bolstered by sales of its multiple COVID-19 diagnostics, Quidel is looking for a way to reinvest that windfall back into the business—and seems to have found it in the ...

Raritan’s Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho in a deal valued at ...

Michael Iskra, executive vice president of commercial excellence and strategy at Ortho, said his company is focused on delivering quality results and the operational financial impacts of diagnostic ...

Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics today announced it is launching to market its SARS-CoV-2 (COVID-19/coronavirus) antibody test—the VITROS ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest ...

Quidel Corp., based in San Diego, announced it closed May 27 on the previously announced acquisition of Raritan-based Ortho Clinical Diagnostics Holdings PLC. The deal — which would create a new ...

Ortho Clinical Diagnostics Holdings plc, an in-vitro diagnostics company, has raised $1.3 billion for its IPO after pricing its 76 million shares at $17 per share. The stock began trading January 28, ...